Surender Juneja

A practical guide to laboratory investigations at diagnosis and follow up in Waldenstrom macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group

M Gohar Maqbool, Constantine S Tam, Ian M Morison, David Simpson, Peter Mollee, Hans Schneider, Henry Chan, Surender Juneja, Yasmin Harvey, Lakshmi Nath, Pravin Hissaria, H Miles Prince, Helen Wordsworth, Stephen Opat, Dipti Talaulikar

Journal article  |  2020  |  PATHOLOGY

Waldenström macroglobulinaemia (WM) is an indolent non-Hodgkin lymphoma which usually presents with symptoms related to infiltrati..

AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/ REFRACTORY CLL

SM Handunnetti, TE Lew, VS Lin, MA Anderson, D Carney, M Wolf, N Came, S Juneja, D Westerman, CS Tam, AW Roberts, JF Seymour

Conference Proceedings  |  2019  |  Hematological Oncology

Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia Under Long-Term Venetoclax Treatment

Thomas Lew, Mary Ann Anderson, Constantine S Tam, Sasanka Handunnetti, Dennis Carney, Max Wolf, Surender Juneja, David Alan Westerman, Andrew W Roberts, John F Seymour

Conference Proceedings  |  2018  |  BLOOD

Abstract Background The selective BCL2 inhibitor venetoclax (Ven) achieves an overall response rate of approximatel..

Lifetime alcohol intake and risk of non-Hodgkin lymphoma: Findings from the Melbourne Collaborative Cohort Study

Harindra Jayasekara, Surender Juneja, Allison M Hodge, Robin Room, Roger L Milne, John L Hopper, Dallas R English, Graham G Giles, Robert J MacInnis

Journal article  |  2018  |  INTERNATIONAL JOURNAL OF CANCER

Cohort studies have reported inconsistent evidence regarding alcohol intake and risk of non-Hodgkin lymphoma (NHL), mostly based o..

Changing role of bone marrow examination in the diagnosis of hematological malignancies

Surender Juneja, David Westerman

Journal article  |  2018  |  LEUKEMIA & LYMPHOMA

Time to standardise haematology terminology.

Surender Juneja, Eric Wong

Journal article  |  2017  |  Br J Haematol

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax

Mary Ann Anderson, Constantine Tam, Thomas E Lew, Surender Juneja, Manu Juneja, David Westerman, Meaghan Wall, Stephen Lade, Alexandra Gorelik, David CS Huang, John F Seymour, Andrew W Roberts

Journal article  |  2017  |  BLOOD

The BCL2 inhibitor venetoclax achieves responses in ∼79% of patients with relapsed or refractory chronic lymphocytic leukemia/smal..

Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases

Rishu Agarwal, Stephen Lade, Danny Liew, Toni-Maree Rogers, David Byrne, Frank Feleppa, Surender Juneja, David A Westerman

Journal article  |  2016  |  JOURNAL OF CLINICAL PATHOLOGY

AIMS: MYC rearrangements with or without BCL2 rearrangements have been shown to be associated with poor prognosis and inferior sur..

Acute myeloid leukaemia and myelodysplastic syndromes with 50% or greater erythroblasts: a diagnostic conundrum

Eric Wong, Surender Juneja

Journal article  |  2015  |  PATHOLOGY

Acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) with ≥50% erythroblasts comprise up to 5% of all cases of AML an..

How unique is pure erythroid leukaemia? A retrospective analysis of seven cases and review of the literature

Eric Wong, Victoria Ling, David Westerman, Susan Morgan, Surender Juneja

Journal article  |  2015  |  JOURNAL OF CLINICAL PATHOLOGY

AIMS: Pure erythroid leukaemia (PEL) is a rare subtype of acute myeloid leukaemia (AML) and its clinicopathological features are n..